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Abstract
Background: Monocyte recruited into the tumor and maturation to tumor-associated macrophage (TAM).
Interleukin-10(IL-10) is a potent immunosuppressive cytokine, which can be secreted from both primary tumor and
stromal cells. However, there are controversies regarding its role in the progression of cancer. So it is important to
isolate TAM from tumor cells to study the role of IL-10 in the progress of cancer. The aim of our study was to
determine whether IL-10 expressed by TAM correlated with clinicopathological factors in NSCLC.
Methods: TAM in NSCLC was isolated by short-term culture in serum free medium with the modification to
literature reports. The mRNA expression levels of IL-10, cathepsin B, cathepsin S, which were closely related with
TAM according to the literatures, were evaluated by Quantitative real-time RT-PCR in 63 NSCLC. The relationships
between their expression levels and clinicopathological features were investigated.
Results: We successfully achieved up to 95% purity of TAM, derived from 63 primary lung cancer tissues. TAM
expressed high levels of IL-10, cathepsin B in NSCLC. High levels of IL-10 in TAM significantly correlated with stage,
tumor size, lymph node metastasis, lymphovascular invasion or histologic poor differentiation.
Conclusions: Our results revealed that TAM with high levels of IL-10 expression may play an important role in the
progression of non-small cell lung cancer. The data also suggested that TAMs may involve in tumor
immunosuppression through overexpressed IL-10. Additionally, the phenotype of isolated TAM can be potentially
used to predict clinicopathological features as well.
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Background
Tumor-associated macrophages (TAMs) are the most
abundant cancer stromal cells involved in the host
immune system [1,2]. In recent years, increasing attention
has focused on TAMs, unique macrophage populations
that play pivotal roles in tumor immunosuppression, and
provide a suitable microenvironment for cancer develop-
ment and progression[3]. TAM infiltration has been found
to be correlated with a worse outcome in several malig-
nant tumors [4-9]. The possible mechanism by which
TAMs support tumor progression and help the tumor
evade immunosurveillance is through the release a spec-
trum of tumor promoting and immunosuppressive
products.
Interleukin-10(IL-10), cathepsin B or cathepsin S was
reported to be closely associated with TAMs in recent
literatures [10-12]. IL-10 is produced primarily by T
cells, B cells, dendritic cells, and monocytes/macro-
phages[13]. Tumor-associated macrophages form a
major component in a tumor, and have been suggested
to play an essential role in the complex process of
tumor-microenvironment coevolution and tumorigenesis
[1]. Previous reports have also shown that TAMs pro-
duce high levels of IL-10, exhibit little cytotoxicity for
tumor cells[14]. However, there are controversies
regarding its role in the progression of cancer [15,16].
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study the role of IL-10 in the progress of cancer.
By using DNA-microarray technology, recent study
demonstrated that NSCLC patients with a high expres-
sion level of cathepsins in lung cancer tissue (both
tumor cells and stroma cells) had a poor outcome [17].
Interestingly, it has been shown that TAM is the pri-
mary source of high levels of cathepsin activity in pan-
creatic, breast and prostate cancer animal models
[10-12]. However, the significance of cathepsins
expressed by TAM in NSCLC remains unknown.
In the present study, we assessed IL-10, cathepsin B
and cathepsin S expression in TAMs, freshly isolated
from lung tumor tissue, in correlation with clinicopatho-
logical factors in NSCLC.
Materials and methods
Subject characteristics
63 paired peripheral blood samples and primary lung
cancer tissues were collected from patients before or at
the time of surgical resection at the Center for Lung
Cancer Prevention and Treatment of Shanghai Cancer
Hospital from June 2009 to March 2010. Data collected
included age, sex, smoking history, histopathological
diagnosis, TNM stage, lymphovascular invasion, pleural
invasion, and tumor differentiation. Histological diag-
noses, presence of lymphovascular invasion(LVI), and
grade of differentiation were confirmed by two senior
histopathologists. A consent form was signed by every
patient or his/her legal representatives. This study was
approved by the committees for Ethical Review of
Research at Shanghai Cancer Hospital.
Histological diagnosis and grade of differentiation
were determined in accordance with the World Health
Organization criteria for lung cancer[18]. The pathologic
tumor stage (p stage) was determined according to the
revised TNM classification of lung cancer[19].
Isolation of tumor-associated macrophages
TAMs were isolated from solid tumors according to lit-
erature reports [20-22]. Briefly, Tumor tissue was cut
into 2 mm fragments, followed by collagenase digestion
(0.3 mg/ml, Worthington Biochemical Corp, NJ, USA)
for 1 h at 37°C. The suspension was filtered through a
70 μm stainless steel wire mesh to generate a single-cell
suspension. The suspension was centrifuged and washed
twice with PBS. Cells were left to adhere in serum-free
RPMI 1640 for 40 min. Nonadherent cells were washed
away. Ninety-five percent of the remaining adherent
cells were TAMs as assessed by morphology and macro-
phage specific marker CD68 positivity.
Immunofluorescence
TAMs were adhered to 24-well plate , fixed in 4% paraf-
ormaldehyde at room temperature for 5 minutes, washed
with PBS twice, incubated with 1% BSA at 37°C for
30 minutes to block nonspecific interactions, and then
stained with primary antibodies to CD68 (1:100 dilution,
sc-20060, Santa Cruz Biotechnology, CA, USA) at 4°C
overnight. After several washes with PBS, the cells were
incubated in an appropriate, rhodamine-labeled goat
anti-mouse secondary antibody(Proteintech Group, Inc,
Chicago ,USA) at room temperature for 1 h. Nuclei of all
cells were then stained with 4’6-diamidino-2-phenylin-
dole(DAPI). Image was taken at 200 × magnification on
an Olympus-IX51 microscope. For each patient, 10 fields
were imaged and measured for percentage of macro-
phage (CD68 positive cells/DAPI stained cells). Immuno-
fluorescence was repeated in three randomly selected
patients.
Preparation normal macrophage
Macrophage (M) was obtained as described previously
[20]. In brief, the mononuclear cells were isolated from
peripheral blood matched with TAMs by Ficoll-Hypaque
density gradient centrifugation (density, 1.077 ± 0.001 g/ml,
Axis-Shield, Oslo, Norway) at 450 × g for 30 min at room
temperature. The mononuclear cells were washed thrice
with PBS and plated at 1 × 10
7 in 6-cm tissue culture dishe
for 2 h in DMEM alone. Thereafter, the nonadherent cells
were washed thrice with warm PBS and the adherent
monocytes were cultured in DMEM containing 5% FBS
and 25 ng/ml human macrophage colony-stimulating
f a c t o r ( ( r h M - C S F ,P e p r o T e c h ,R o c k yH i l l ,N J ,U S A ) ,T h e
medium was changed every 2 days, and macrophage were
obtained after 6 days in vitro cultivation.
RNA isolation and Quantitative real-time RT-PCR(QRT-PCR)
Total RNA was isolated from TAMs and their matched
macrophages by using RNeasy Mini Kit (Qiagen, Valencia,
CA, USA) as described by the manufacturer’sp r o t o c o l .
For mRNA analysis, an aliquot containing 2 μgo ft o t a l
RNA was transcribed reversely using M-MLV reverse
transcriptase (Promega, Madison, WI, USA). Specific pri-
mers (Genery, Shanghai, China) were used to amplify
cDNA. QRT-PCR was done using SYBR Green PCR mas-
ter mix (Applied Biosystems, Piscataway, NJ, USA). The
primers for QRT-PCR were: b-actin forward (F) 5’
ACCACA CCTTCTACAATGA3’, b-actin reverse(R)
5’GTCATCTTCTCGCGGTTG3’; IL-10 F5 ’ AGAACCT
GAAGACCCTCAGGC3’, IL-10 R5 ’ CCACGGCCTT
GCTCTTGTT 3’; cathepsin B F5 ’ TGCA GCGCTGG
GTGGATCTA 3’; cathepsin B R5 ’ ATTGGCCAACAC-
CAGCAGGC 3’; cathepsin S F5 ’ GCTTCTCTTGGT
GTCCATAC 3’, cathepsin S R5 ’ CATTACTGCGG-
GAATGAGAC 3’. The amplification protocol consisted of
an initial 10 min denaturation step at 95°C, followed by
40 cycles of PCR at 95°C for 15s, 60°C for 1 min and
detection by the ABI-Prism 7900HT Sequence Detection
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sample was assayed in triplicate. The comparative CT
method (ΔΔCT method) was used to determine the
quantity of the target sequences in TAM relative both to
M (calibrator) and to b-actin (an endogenous control).
Relative expression levels were presented as the relative
fold change and calculated using the formula: 2
-ΔΔCT=
2-(ΔCT
(TAM) - ΔCT
(M
) where each ΔCT =ΔCT
target-
ΔCT
b-actin.
Immunohistochemistry
For exact identification of IL-10 or cathepsin B expres-
sion in TAMs, serial sections were used to examine the
expression of IL-10, cathepsin B in TAMs. Samples
w e r ef i x e di n4 %f o r m a l d e h y d ei nP B S( p H7 . 2 )a n d
paraffin embedded. 4-μm thickness was cut from each
paraffin block. After dewaxing and rehydration, the
sections were microwaved for antigen retrieval in
10 mmol/liter citrate buffer (pH 6.0) for 10 min, and
then allowed to cool for 1 hour at room temperature.
Endogenous peroxidase activity was blocked with hydro-
gen peroxide; Nonspecific binding was blocked by prein-
cubation with 10% goat serum in PBS for 30 minutes at
room temperature. Slides were incubated with the pri-
mary antibodies directed against monoclonal anti-
human CD68 antibody (1:200 dilution, sc-20060, Santa
Cruz, CA, USA), monoclonal anti-human IL-10 antibody
(1:100 dilution, BA1201,Boster, WuHan, China) or poly-
clonal anti-human cathepsin B antibody (1:100 dilution,
ab49232, Abcam, MA, USA). The results were visualized
using the streptavidine-biotin immunoperoxidase detec-
tion kit and AEC chromogen (Maixin Bio, FuZhou,
China) based on the manufacturer’s instruction. Positive
cells stained red. The negative control involved omission
of the primary antibody.
Statistical analysis
Statistical analysis software (Prism 5.0, GraphPad Soft-
ware Inc, La Jolla, CA, USA and SPSS Version 13.0
software, SPSS Inc, Chicago, IL, USA) was used to per-
form the analyses. Data are expressed as median
(range). The Mann-Whitney test was used for the
comparison between TAM and normal macrophage.
The correlation between IL-10 or cathepsin B expres-
sion and clinicopathologic factors was analyzed by
Mann-Whitney test. Multivariate logistic regression
was performed to evaluate the relationships between
the pathological stage (with early and late stage as
dependent variables) and covariates (age, sex, tobacco
use, tumor histology and IL-10 expression in TAMs).
For this analysis, the median value of IL-10 was chosen
as the cut-off point for dividing the patients into the
two groups. Two-tailed P value less than 0.05 was con-
sidered statistically significant.
Results
Patients characteristics
The patient characteristics are described in Table 1.
Patients (40 males and 23 females) had a mean age of
58.8 ± 1.1 years. Fifty-four patients had a smoking his-
tory, and forty-six were non-smokers. Adenocarcinoma
was the most common tumor type (54%) followed by
squamous cell carcinoma (32%). 30 patients (48%)
were stage I (early stage), and the remaining 34
patients were (52%) stages II, III or IV (late stage) of
the disease.
Table 1 characteristics for the patients included in this
study
characteristic No.
a(N= 63) %
Age/years(Median,
range)
58 (37-76)
Sex
Male 40 63.5
Female 23 36.5
Tobacco use
Current 22 35
Former 12 19
Never 29 46
Histology
Adenocarcinoma 34 54
Squamous cell
carcinoma
20 32
Others
b 91 4
Stage
StageⅠ 30 48
StageⅡ 11 17
StageⅢ 17 27
StageⅣ
c 58
Lymph node metastasis
N0 42 67
N1/N2 21 33
Pleural invasion
Negative 43 68
Positive 20 32
Lymphovascular
invasion
Negative 51 81
Positive 12 9
Histologic
differentiation
Well/Moderate 30 48
Poor 26 41
not available
d 71 1
a Number for all except age.
b Include 2 Large cell carcinoma, 2 Carcinoid, 1 malignant clear cell sugar
tumor, 1 Sarcomatoid carcinoma, and 3 malignancy , but type undetermined.
cStage IV was found incidentally during the operation or only for biopsy.
d Include Carcinoid, malignant clear cell sugar tumor, Sarcomatoid carcinoma,
multiple primary lung cancer.
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macrophages
In our study, 71 NSCLC samples were collected and
TAMs were successful isolated from all samples. How-
ever, cell number of TAMs isolated from 8 NSCLC was
inadequate for gene expression analysis, and excluded
from this study. So TAMs from 63 NSCLC were finally
analyzed. The successful rate was 89%(63/71). Each sam-
ple weight ranged from 10 mg to 200 mg and the cell
number of TAMs collected ranged from 5 × 10
5 to 1 ×
10
7 per 100 mg tumor tissue.
TAMs from lung cancer tissue had an irregular shape
and projections (Figure 1A). To confirm that the cell
isolated from the lung cancer tissue were TAMs without
contamination by fibroblasts or tumor cells, staining for
the macrophage specific marker CD68 was performed.
Over ninety-five percent of the cells stained positively
for each randomly selected patient (Figure 1B).
The mRNA expression levels of IL-10, cathepsin B and
cathepsin S in normal macrophages
We performed a time course study to show the expres-
sion level of IL-10, cathepsin B and cathepsin S in mono-
cytes changes after culture in medium with rhM-CSF.
Our study showed the expression level of IL-10, cathe-
psin B and cathepsin S showed no significant changes in
the time dependent study. (All p > 0.05) (Figure 2A). We
also performed dose depedent study of rhM-CSF to see
whether the expression level of IL-10, cathepsin B and
cathepsin S were affected or not. Our study showed that
the dose of rhM-CSF did not affect the expression level
of IL-10, cathepsin B and cathepsin S (Figure 2B).
The mRNA expression levels of IL-10, cathepsin B and
cathepsin S in TAMs
The mRNA expression levels of IL-10, cathepsin B and
cathepsin S in TAMs were analyzed using QRT-PCR,
compared with matched normal macrophages from the
63 patients. To explore the best time point for analyzing
the expression level of IL-10, cathepsin B and cathepsin
S, a time course study was done. After adhere to plastic
f o r2 0m i n ,4 0m i n ,6 0m i na n d9 0m i n ,t h ee x p r e s s i o n
level of IL-10 were: 28.3 ± 2.3; 28.1 ± 1.1; 24.6 ± 2.1;
14.7 ± 2.9 respectively, and the purity of TAMs were:
100%, 97%, 95%, 84% respectively (staining for the
macrophage specific marker CD68 was performed).
After 60 min, tumor cells and fibroblast began to
adhere, the purity decreased rapidly. So we chose 40
min as the time point for adherence, which is consistent
with previous reports [23] (Figure 3).
Compared with the expression in macrophage, IL-10
and cathepsin B were significantly upregulated (p < 0.05).
After normalized to macrophages, the median values
(range) of each gene in TAM were: IL-10, 30.5(0.6-530.3)
and cathepsin B, 11.9(0.6-69.1) (Figure 4 A-B). There
were no significant differences in the level of cathepsin S
Figure 1 Characterization of tumor-associated macrophage. A. Representative cell morphology of tumor-associated macrophages, TAM,
fibroblast and lung tumor cell. B. Immunofluorescent was used to distinguish macrophage, fibroblast and lung tumor cell with antibodies
targeting CD68 (red), nuclei stained with DAPI (blue). Original magnification, × 400.
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(Figure 4C).
Immunohistochemistry
To confirm whether TAMs express IL-10 and cathepsin
B in protein level, 6 NSCLC (3 late stage (ⅢA) and 3
early stage (Ia- Ib)) were randomly selected to perform
IHC using antibody against CD68, IL-10 and cathepsin
B on serial sections. We demonstrated that almost all
CD68 positive cells co-expressing IL-10, which in line
with the QRT-PCR results that the IL-10 mRNA expres-
sion level is high (Figure 5 A-B). The IL-10 expression
was negative by IHC in 3 early stage NSCLC, which in
line with the QRT-PCR results that the IL-10 mRNA
expression level below the median (30.5) in 3 early stage
NSCLC. Expression of cathepsin B in macrophage was
observed in 5 of 6 cases. Among macrophages expres-
sing cathepsin B, only a small portion of the cells
showed strong positive (Figure 5 C-D) and not asso-
ciated with stage of disease.
The correlation between IL-10, cathepsin B expression in
TAM and clinicopathologic factors
The correlation between IL-10, cathepsin B expression in
TAM and clinicopathologic factors was shown in Table
2. A strongly positive correlation between IL-10 mRNA
expression in TAM and tumor stage was seen. Increased
expression levels of IL-10 in TAM were seen in NSCLC
patients with late stage (stage II, III and IV). When multi-
variate logistic regression analysis was performed, IL-10
expression in TAMs was shown to be an independent
predictive factor for late stage disease (Table 3).
The increased mRNA expression of IL-10 was also
associated with lymph node metastasis, lymphovascular
invasion, pleural invasion and poor differentiation (p <
0.0001, p = 0.010, p = 0.017 p = 0.001, respectively).
A correlation between cathepsin B mRNA expression in
TAM with NSCLC tumor T status was found (p = 0.037).
Figure 3 The mRNA expression levels of IL-10, cathepsin B and
cathepsin S in TAM changes in primary culture. Results are given
as fold increase in mRNA expression with respect to expression in
ctrl (normal macrophages). Data were normalized to expression of
the b-actin gene. Normal macrophages were used as a calibrator.
Error bar is SD; Independent experiments were repeated three
times.
Figure 2 The mRNA expression levels of IL-10, cathepsin B and cathepsin S in normal macrophages. Results are given as fold increase in
mRNA expression with respect to expression in D0 monocytes. Data were normalized to expression of the b-actin gene. A: Monocytes(D0) was
used as a calibrator. B, monocytes culture without rhM-CSF was used as a calibrator (Ctrl). Error bar is SD, Independent experiments were
repeated three times, all #p > 0.05(by student t-test).
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the mRNA expression of cathepsin B with any other clini-
copathological factors (all p > 0.05).
Discussion
Increased infiltration of TAMs into NSCLC correlates
with a poor prognosis [5,9]. However, the mechanisms
for this effect remain unclear. TAM derived molecules
that function to suppress immune activation, promote
extracellular matrix (ECM) remodeling may play impor-
tant roles in NSCLC progression.
I nt h ep r e s e n ts t u d y ,t h er a t i o n a lw es e l e c t e dIL-10,
cathepsin B or cathepsin S, is that they were reported to
be closely associated with TAMs in recent literatures
[10-12,24]. IL-10 is widely known as an potent immuno-
suppressive cytokine associated with cancer [13,25]. It is
produced by a number of cells, including tumor cells
and TAMs[14,25]. Cathepsins B, cathepsin S, proteolytic
enzymes, were thought to facilitate the breakdown of
basement membranes thereby promoting cancer cell
invasion into surrounding normal tissues. TAM
expressed cathepsin B or cathepsin S in pancreatic islet,
breast or prostate cancer animal models. In our study,
we showed, TAM expressed high levels of IL-10, cathe-
psin B, but not cathepsin S in NSCLC.
Our study suggested that increased IL-10 expression
of TAM in NSCLC patients correlated with late stage
disease (stage II, III and IV), lymph node metastases,
pleural invasion, lymphovascular invasion and poor
differentiation. Although recent animal model studies
indicated that cathepsin B or cathepsin S expressed by
TAM play an important role in tumor progression
[10,11], and we also found cathepsin B upregulated in
TAM, we failed to demonstrate any correlation between
cathepsin B in TAM and stage, lymph nodal metastasis,
pleural invasion or differentiation in NSCLC.
TAMs are derived from blood monocytes that are
attracted to a tumor by cytokines and chemokines[14]. In
the tumor microenvironment, monocytes differentiate into
a distinct macrophage phenotype, which is characterized
by the production of high level of IL-10.T A Mw i t hh i g h
IL-10 expression level may tune inflammatory responses
and adaptive Th2 immunity, exhibit anti-inflammatory and
tissue remodeling functions and thereby, to favor tumor
progression[14]. We demonstrated that NSCLC patients
with late stage disease had a higher level of IL-10 expres-
sion in TAM, which further supports this hypothesis.
IL-10 is a potent immunosuppressive factor that may
promote lung cancer growth by suppressing macrophage
function and enabling tumors to evade immunosurveil-
lance[26]. The potential importance of IL-10 in cancer
progression is supported by reports of an association
between high IL-10 levels in serum or in tumors and
worse survival in lung cancer patients[15]. However,
other authors demonstrated that lack of IL-10 expres-
sion by the tumor was associated with a worse survival
in patients with stage I NSCLC [16]. The reason for
these conflicting results might be that, both tumor cells
Figure 4 mRNA from TAMs and matched normal macrophage(M) was analyzed by Quantitative real-time RT-PCR for expression of
the indicated genes in 63 NSCLC samples. Results are given as fold increase in mRNA expression with respect to expression in matched M.
Data were normalized to expression of the b-actin gene. M was used as a calibrator. Bars represent median. *p by the Mann-Whitney U test.
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10. Additionally, Wagner S et al identified that macro-
phage was the major source of IL-10 in gliomas[27]. So
it is important to isolate TAM from tumor cells to
study the role of IL-10 in the progression of cancer. In
our study, we demonstrated the phenotype of isolated
TAM was closely associated with clinicopathological fea-
tures. We can predict tumor size, lymph nodal metasta-
sis and pleural invasion through.IL-10 expression in
isolated TAM. We also found that the high expression
of IL-10 in TAM was associated with poorly differentia-
tion, which highlighted a significance role of IL-10
secreted by TAM in tumor aggressiveness.
A crucial step of cancer invasion and metastasis is the
destruction of basement membrane by proteases. Recent
studies showed invasion of cancer cell is increased by the
proteases secreted from TAMs. Cathepsin B or cathepsin
S has been implicated in the progression of various human
cancers, including bladder, breast, prostate and lung can-
cers [17,28-30]. The cellular source of this protease in
human cancers, consisting of both tumor cells and stromal
cells (e.g., fibroblasts, endothelial cells, and TAMs), has
remained elusive. Studies using animal models have
demonstrated that TAMs are the primary source of high
levels of cathepsin B or cathepsin S in prostate, pancreatic
islet cancers, and mammary tumors, and its expression by
TAMs plays critical roles in multiple stages of tumor
growth and metastasis[10,12,29]. Our studies demon-
s t r a t e dt h a tT A Mi s o l a t e df r o mN S C L Co v e r e x p r e s s e d
cathepsin B but not cathepsin S, and the cathepsin B levels
were not associated with NSCLC stage, lymph metastasis,
lymphovascular invasion or histological differentiation.
Figure 5 Immunohistochemical expression of IL-10, cathepsin B and CD68 in macrophage. A-B, High IL-10 expression in macrophage, A,
IL-10 staining in macrophage (strong positivity); B, CD68 staining. C-D, Cathepsin B expression in macrophage; C, cathepsin B staining in
macrophage (most cells were moderate positivity, only a few cells were strong staining); D, CD68 staining. Scale bar indicates 50 μm. Original
magnification, × 400.
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Interleukin-10 expression in tumor-associated macrophages
correlates with disease aggressiveness of non-small cell lung
cancer. We plan to conduct further studies to analyze the
relationship between IL-10 in TAM and survival. The study
concerning regulation of IL-10 in TAM is ongoing too. It
will help to clarify and understand the possible mechanisms
IL-10 secreted by TAM in the progression of NSCLC.
Table 2 Genes expression of TAM in relationship with clinicopathological factors
IL-10 Cathepsin B
Variables N Median(Range) p* value Median (Range) p* value
age
<58 26 31.3(3.05-530.3) 0.252 10.9(0.9-51.9) 0.41
≥58 37 30.5(0.6-511.6) 14.5(0.6-69.1)
Gender
Male 40 31.3(1.3-530.3) 0.607 14.9(0.9-69.1) 0.061
Female 23 19.9(0.6-426.1) 10.1(0.6-37.9)
Smoking history
Never 29 30.5(0.6-426.1) 0.699 10.1(0.6-51.9) 0.067
Former or current 34 31.2(1.3-530.3) 14.9(1.5-69.1)
Histology
Adenocarcinoma 34 42.9(0.6-530.3) 0.045 12.7(0.6-69.1) 0.41
Squamous cell carcinoma 20 17.1(1.3-354.3) 16.6(1.5-41.7)
Others 9 41.2(6.4-511.6) 10.2(4.2-26.7)
Pathological stage
Stage I 30 9.7(0.6-140.8) 0.016 13.1(0.6-69.1) 0.066
StageⅡ 11 28.9(1.8-511.6) 13.6(3.1-41.7)
StageⅢ 17 177.7(23.5-530.3) 11.8(1.2-51.9)
StageⅣ 5 249.9(55.4-429.9) 10.1(3.6-25.9)
T status
T1 15 4.1(0.6-263.6) <0.0001 9.9(0.6-22.7) 0.037
T2-3 48 42.9(1.6-530.3) 14.2(0.9-69.1)
Lymph node metastasis
N(+) 21 119.1(6.1-530.3) <0.0001 13.6(1.2-46.9) 0.466
N(-) 42 19.2(0.6-273.8) 11.1(0.6-69.1)
Lymphovascular invasion
LVI(+) 12 93.1(6.2-530.3) 0.01 14.2(0.9-37.8) 0.92
LVI(-) 51 26.5(0.6-429.9) 11.1(0.6-69.1)
Pleural invasion
PL(+) 20 55.8(14.9-530.3) 0.002 14.2(0.9-69.1) 0.376
PL(-) 43 19.9(0.6-354.9) 11.1(0.6-51.9)
Differentiation
Well or Moderately 30 17.3(0.6-429.9) 0.001 13.0(0.6-69.1) 0.961
poorly 26 113.1(1.6-530.3) 11.9(1.2-37.9)
*p by the Mann-Whitney U test.
Table 3 Logistic regression analysis of the association between tumor stage and clinicopathological features
(n = 63)
B SEM Chi-squared p-value OR (95% CI)
Sex 0.241 1.110 0.037 0.847 1.239(0.141-10.922)
Age -0.063 0.040 2.484 0.115 0.939(0.868-1.015)
Tobacco use 1.173 1.102 1.133 0.287 3.231(0.373-28.005)
Histology 0.292 0.531 0.303 0.582 1.339(0.473-3.793)
High level IL-10 expression in TAM 2.952 0.742 15.844 0.0001 19.137(4.474-81.859)
The dependent variable is early- or late-stage group The independent variables included sex (0 = female; 1 = male), age (continuous variable, in yrs), Tobacco
use (0 = Current,1 = Former,2 = Never), histology (1 = adenocarcinoma; 2 = squamous cell carcinoma;3 = others) and IL-10 expression (0 = low (<30.5); 1 = high
(≥30.5). OR: odds ratio; CI: confidence interval.
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